Table 1 Characteristics of the included studies
Study | Median age (range) | Gender (male, %) | HCV-RNA (median log10) | Genotype | Type of treatment and dose | Treatment duration (week) | RVR | SVR24 | Relapse | VB | TDAE | SAE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hézode et al. (2015) (n = 395) | 51 (22–70) | 67.3 | 6.5 | G1a, 275/395 | D (20 mg/day) + P (180 μg/week) + R (1.0–1.2 g/day) | 24 | 91 (57) | 95 (60) | 24 (15) | 14 (9) | 7 (4) | 12 (8) |
50 (18–67) | 65.2 | 6.5 | G1b, 88/395 | D (60 mg/day) + P (180 μg/week) + R (1.0–1.2 g/day) | 24 | 87 (55) | 99 (63) | 22 (14) | 15 (9) | 7 (4) | 13 (8) | |
51 (25–66) | 70.5 | 6.4 | G4, 32/395 | PBO + P (180 μg/week) + R (1.0–1.2 g/day) | 24 | 11 (14) | 30 (38) | 9 (12) | 2 (3) | 8 (10) | 6 (8) | |
Dore et al. (2015) (n = 151) | 52 (28–64) | 54.2 | 6.4 | G2, 71/151 | D (60 mg/day) + P (180 μg/week) + R (0.8 g/day) | 12 | 43 (86) | 38 (76) | 0 (0) | 8 (16) | 4 (8) | 4 (8) |
52 (25–67) | 65.2 | 6.6 | G3, 80/151 | D (60 mg/day) + P (180 μg/week) + R (0.8 g/day) | 16 | 35 (70) | 37 (74) | 0 (0) | 7 (14) | 3 (6) | 0 (0) | |
55 (20–63) | 45.8 | 6.6 | PBO + P (180 μg/week) + R (0.8 g/day) | 24 | 20 (39) | 31 (61) | 2 (4) | 5 (10) | 2 (4) | 3 (6) | ||
Suzuki et al. (2014) (n = 45) | 51 (21–68) | 22.0 | 6.7 | G1, 45/45 | D (10 mg/day) + P (60–150 μg/week) + R (0.6–1 g/day) | 24/48 | 12 (67) | 8 (44) | 4 (22) | 5 (28) | 1 (6) | 1 (6) |
55 (36–70) | 60.0 | 6.7 | D (60 mg/day) + P (60–150 μg/week) + R (0.6–1 g/day) | 24/48 | 11 (58) | 12 (63) | 3 (16) | 4 (21) | 1 (5) | 0 (0) | ||
50 (42–66) | 50.0 | 6.9 | PBO + P (60–150 μg/week) + R (0.6–1 g/day) | 48 | 0 (0) | 5 (63) | 2 (25) | 1 (13) | 0 (0) | 0 (0) | ||
Izumi et al. (2014) (n = 42) | 56 (26–68) | 44.0 | 6.8 | G1, 42/42 | D (10 mg/day) + P (180 μg/week) + R (0.6–1 g/day) | 24 | 12 (71) | 12 (71) | 3 (18) | 2 (12) | 1 (6) | 2 (12) |
57 (31–67) | 25.0 | 6.6 | D (60 mg/day) + P (180 μg/week) + R (0.6–1 g/day) | 24 | 13 (76) | 15 (88) | 1 (6) | 1 (6) | 2 (12) | 0 (0) | ||
54 (41–65) | 38.0 | 6.5 | PBO + P (180 μg/week) + R (0.6–1 g/day) | 24 | 1 (13) | 6 (75) | 1 (13) | 0 (0) | 0 (0) | 0 (0) | ||
Pol et al. (2012) (n = 48) | 52 (38–66) | 75.0 | 6.3 | G1a, 32/48 | D (3 mg/day) + P (180 μg/week) + R (1.0–1.2 g/day) | 12 | 5 (42) | 5 (42) | 2 (17) | 2 (17) | 1 (8) | 1 (8) |
51 (37–68) | 67.0 | 6.4 | D (10 mg/day) + P (180 μg/week) + R (1.0–1.2 g/day) | 12 | 11 (92) | 10 (83) | 1 (8) | 0 (0) | 1 (8) | 1 (8) | ||
51 (43–67) | 58.0 | 6.5 | G1b, 16/48 | D (60 mg/day) + P (180 μg/week) + R (1.0–1.2 g/day) | 12 | 10 (83) | 10 (83) | 1 (8) | 1 (8) | 4 (33) | 1 (8) | |
50 (28–67) | 67.0 | 6.7 | PBO + P (180 μg/week) + R (1.0–1.2 g/day) | 12 | 1 (8) | 3 (25) | 5 (42) | 0 (0) | 2 (17) | 0 (0) | ||
Ratziu et al. (2012) (n = 419) | NR | NR | NR | NR | D (20 mg/day) + P/R | 12 | 47 (23) | NR | NR | NR | NR | 12 (6) |
D (60 mg/day) + P/R | 12 | 53 (27) | 10 (5) | |||||||||
PBO + P/R | 12 | 0 (0) | 3 (18) |